RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda Thanks Azzak for asking Noteable that question. I will chime in with my non technical views that it is obvious pela improved pfs over the standard of care Paclitaxol by 50%. Pfs is correlated with OS but with pela OS may well be stronger and and relatively better as the immune response comes forward after about 4 months, as seen in the waterfall graphs for former trials.
Then there is the panc result from last fall which was equally if not more of a sharp improvement in terms of response in a deadly disease.
These results are not fake or suspect. They are real and cannot by talked away.
That means big pharma MUST be interested, because they are obsessed with market share, growth and building revenues in the face of a clear and documented patent cliff. At the same time, they have tonnes of money for aquisition.
So the game is still underway and gaining momentum. There are only positives in the results from trials and that is what we have to sell.